Michael Carrier’s case study on Provigil offers new support for the view that Big Pharma is to blame for stymieing competition, retarding innovation, and inflating prices in the drug industry. Carrier argues that Cephalon was able to thwart generic entry by a combination of anticompetitive … Read more
Author: Daniel A. Crane
The Hastings Science & Technology Law Journal (STLJ) is a multidisciplinary journal created to enrich the discourse at the nexus of science, scientific methodology, technology, biotechnology, bioethics, health, public policy, and the law. STLJ is designed to serve both the legal and scientific communities through prompt publication of scholarly works on the basis of originality, insight, timeliness, and elegance, and by providing an open forum for the discussion and interpretation of significant developments in science and law.